Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance
This article was originally published in PharmAsia News
Executive Summary
In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ('Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells,' PharmAsia News, May 23, 2011). In this installment, we talk with Biogen Idec SVP Gunther Winkler, who discusses the big biotech's strategy in India and important policy decisions facing the Indian government.